Answers are grounded in this paper and cite their sources.
The expectation for survival in patients with advanced melanoma now exceeds 50% at 5 years in patients treated with first-line combination ipilimumab and nivolumab, despite this regimen being associated with substantial toxicity. We discuss the latest updates from the Checkmate-067 study, framing the role of this combination in practice today.
No takes yet. Share an insight, caveat, or question.
Spain et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: